Is Industry Ready To Take A Bite Out Of Obesity?

Despite decades of education on the health risks associated with excess body weight, such as heart disease, diabetes, and cancer, obesity rates continue to rise globally, accompanied by increasing medical expenses.

A new class of drugs now offers healthcare providers and patients a promising tool to combat this widespread issue. However, the introduction of such a drug raises important clinical, economic, and policy questions, and the industry must adapt to meet the growing demand.

Learn about glucagon-like peptide 1 (GLP-1) agonists, the complexities of policies surrounding weight loss drugs, the shifts in supply chains to support the rising demand for GLP-1 agonists, and the future of weight loss drugs.